Argenx
ARGX
#444
Rank
A$79.36 B
Marketcap
A$1,274
Share price
-3.61%
Change (1 day)
28.26%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Earnings for Argenx (ARGX)

Earnings in 2025 (TTM): A$1.48 Billion

According to Argenx 's latest financial reports the company's current earnings are A$3.60 Billion. In 2024 the company made an earning of A$0.12 Billion, an increase over its 2023 earnings that were of -A$0.46 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Argenx from 2013 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) A$1.48 B1056.37%
2024 A$0.12 B-127.97%
2023 -A$0.46 Billion-58.25%
2022 -A$1.1 Billion80.17%
2021 -A$0.61 Billion
2019 -A$0.3 Billion124.86%
2018 -A$0.14 Billion131.81%
2017 -A$57.45 Million
2015 -A$27.74 Million
2013 -A$16.78 Million